title: The costs of treatment of hypertension in Switzerland and worldwide.
abstract: Extrapolation from one country to another concerning costs of treatment of essential hypertension has to be made with caution because of wide variation of socio-economic differences and governmental price setting attitudes. The worldwide antihypertensive drug market shows a strong increase in the last few years and reflects the evolution away from diuretics and toward the more expensive ACE inhibitors and calcium antagonists, with a decreasing percent market of beta-blockers and absolute stagnation in other antihypertensives outside these four groups of drugs.
authors.affiliation: Cardiology Center, University Hospital, Geneva, Switzerland.
authors.forename: W J
authors.initials: WJ
authors.lastname: Rutishauser
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003365:Costs and Cost Analysis / Q000639:trends; D004232:Diuretics / Q000627:therapeutic use; D005060:Europe; D014943:Global Health; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000191:economics*; D013557:Switzerland
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics